Selection of induction therapy in kidney transplantation

被引：68
作者：
Hardinger, Karen L. [1 ]
Brennan, Daniel C. [2 ]
Klein, Christina L. [2 ]
机构：
[1] Univ Missouri, Sch Pharm, Dept Pharm Practice, Kansas City, MO 64110 USA
[2] Washington Univ, St Louis, MO 63110 USA
来源：
TRANSPLANT INTERNATIONAL | 2013年 / 26卷 / 07期
关键词：
alemtuzumab; anti-thymocyte globulin; Atgam; basiliximab; induction; induction immunosuppression; monoclonal; polyclonal; thymoglobulin; transplantation; RABBIT ANTITHYMOCYTE GLOBULIN; ANTI-THYMOCYTE GLOBULIN; DONOR RENAL-TRANSPLANTATION; ACUTE CELLULAR REJECTION; LONG-TERM; RANDOMIZED-TRIAL; MYCOPHENOLATE-MOFETIL; BASILIXIMAB INDUCTION; ALEMTUZUMAB INDUCTION; DOUBLE-BLIND;
D O I：
10.1111/tri.12043
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Currently available immunosuppressive agents can be classified into three categories: induction agents, maintenance therapy, and treatment for rejection. This review article will focus on induction immunosuppression. There are three antibodies which are used for induction therapy: the lymphocyte-depleting agents - anti-thymocyte globulin and alemtuzumab, and basiliximab which is nondepleting. Historically, immunosuppressant selection was solely based on efficacy for prevention of rejection. In the current era of transplantation, it is now common practice in the transplant community to select induction therapy on the basis of risk-benefit considerations for each patient. This article will focus on the efficacy of available induction agents and the selection of induction agent based on donor and recipient risk factors.
引用
收藏
页码：662 / 672
页数：11
相关论文
共 87 条
  • [1] Short course induction immunosuppression with thymoglobulin for renal transplant recipients
    Agha, IA
    Rueda, J
    Alvarez, A
    Singer, GG
    Miller, BW
    Flavin, K
    Lowell, JA
    Shenoy, S
    Howard, TK
    Ramachandran, V
    Irish, W
    Schnitzle, MA
    Brennan, DC
    [J]. TRANSPLANTATION, 2002, 73 (03) : 473 - 475
  • [2] Long-term results of monoclonal anti-II2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation
    Al Najjar, A.
    Etienne, I.
    Le Pogamp, P.
    Bridoux, F.
    Le Meur, Y.
    Toupance, O.
    Mousson, C.
    Caillard, S.
    de Ligny, B. Hurault
    Marliere, J. F.
    Lebranchu, Y.
    [J]. TRANSPLANTATION PROCEEDINGS, 2006, 38 (07) : 2298 - 2299
  • [3] [Anonymous], AM J TRANSPLANT S3
  • [4] Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: A retrospective study
    Baron, Pedro W.
    Ojogho, Okechukwu N.
    Yorgin, Peter
    Sahney, Shobha
    Cutler, Drew
    Ben-Youssef, Ramzi
    Baqai, Waheed
    Weissman, Jill
    Franco, Edson
    Zuppan, Craig
    Concepcion, Waldo
    [J]. PEDIATRIC TRANSPLANTATION, 2008, 12 (01) : 32 - 39
  • [5] Serum Sickness After Treatment With Rabbit Antithymocyte Globulin in Kidney Transplant Recipients With Previous Rabbit Exposure
    Boothpur, Raghavender
    Hardinger, Karen L.
    Skelton, Rebecca M.
    Lluka, Brunilda
    Koch, Matthew J.
    Miller, Brent W.
    Desai, Niraj M.
    Brennan, Daniel C.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (01) : 141 - 143
  • [6] Long-term results of rabbit antithymocyte globulin and basiliximab induction
    Brennan, Daniel C.
    Schnitzler, Mark A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (16) : 1736 - 1738
  • [7] Rabbit antithymocyte globulin versus basiliximab in renal transplantation
    Brennan, Daniel C.
    Daller, John A.
    Lake, Kathleen D.
    Cibrik, Diane
    Del Castillo, Domingo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19) : 1967 - 1977
  • [8] A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
    Brennan, DC
    Flavin, K
    Lowell, JA
    Howard, TK
    Shenoy, S
    Burgess, S
    Dolan, S
    Kano, JM
    Mahon, M
    Schnitzler, MA
    Woodward, R
    Irish, W
    Singer, GG
    [J]. TRANSPLANTATION, 1999, 67 (07) : 1011 - 1018
  • [9] Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation:: a 1-yr follow-up of safety and efficacy
    Büchler, M
    de Ligny, BH
    Madec, C
    Lebranchu, Y
    [J]. CLINICAL TRANSPLANTATION, 2003, 17 (06) : 539 - 545
  • [10] Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients
    Bustami, RT
    Ojo, AO
    Wolfe, RA
    Merion, RM
    Bennett, WM
    McDiarmid, SV
    Leichtman, AB
    Held, PJ
    Port, FK
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) : 87 - 93
123456789